All In Biotech

Drug Trial Radar · NCT03744468

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

147

Actual

Start

Nov 13, 2018

Primary completion

Feb 6, 2025

Study completion Feb 6, 2025

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.

Conditions

  • Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
  • HNSCC for Phase 2 Dose Expansion
  • NSCLC for Phase 2 Dose Expansion

Interventions

  • SurzebiclimabDrug

    Humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody against TIM-3

  • TislelizumabDrug

    Humanized, IgG4-variant monoclonal antibody against PD-1

  • AlcestobartDrug

    Human anti LAG-3 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)
  2. Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With TislelizumabTime frame: Up to 28 days
  3. Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With TislelizumabTime frame: Up to 28 days
  4. Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEsTime frame: Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)
  5. Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With TislelizumabTime frame: Up to 21 days
  6. Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and TislelizumabTime frame: Up to 21 days
  7. Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and TislelizumabTime frame: Up to 21 days
  8. Phase 2 (Dose Expansion): Overall Response Rate (ORR)Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months

Locations

40 sites in 6 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Chicago Medical Center

    Chicago, Illinois

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • Weill Cornell Medical College Newyork Presbyterian Hospital

    New York, New York

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Ut Health San Antonio Mays Cancer Center

    San Antonio, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Schar Cancer Institute

    Fairfax, Virginia

  • Sydney Southwest Private Hospital

    Liverpool, New South Wales, Australia

  • Sunshine Coast Hospital and Health Service

    Birtinya, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Calvary North Adelaide Hospital

    North Adelaide, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Cabrini Research and Education Institute

    Malvern, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Western Health Sunshine Hospital

    St Albans, Victoria, Australia

  • Hollywood Private Hospital

    Nedlands, Western Australia, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Centre de Lutte Contre Le Cancer Institut Bergonie

    Bordeaux, France

  • Centre de Lutte Contre Le Cancer Francois Baclesse

    Caen, France

  • Institut Curie Paris

    Paris, France

  • Irccs Azienda Ospedaliero Universitaria Bologna

    Bologna, Italy

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, Italy

  • Istituto Di Candiolo Irccs

    Torino, Italy

  • Ajou University Hospital

    Suwon, South Korea

  • Chungbuk National University Hospital

    SeowonGu CheongjuSi, Chungcheongbukdo, South Korea

  • The Catholic University of Korea, St Vincents Hospital

    PaldalGu SuwonSi, Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    NamdongGu, Incheon Gwang'Yeogsi, South Korea

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, South Korea

  • Ulsan University Hospital

    Donggu, Ulsan Gwang'Yeogsi, South Korea

  • Institut Catala Doncologia

    Barcelona, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Hm Madrid Sanchinarro

    Madrid, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.